

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-27 (Canceled).

28. (Currently amended) A method of inhibiting the growth of a tumor cell comprising administering a ~~GP88~~ PC Cell Derived Growth Factor antisense oligonucleotide to the tumor cell wherein said oligonucleotide inhibits the growth of the tumor cell.

29. (Previously presented) The method of claim 28, wherein the tumor cell is a breast carcinoma cell.

30. (Previously presented) The method of claim 28, wherein said oligonucleotide is at least about 15 nucleotides.

31. (Currently amended) A method of decreasing the size of a tumor comprising administering a ~~GP88~~ PC Cell Derived Growth Factor antisense oligonucleotide to the tumor wherein said oligonucleotide decreases the size of the tumor.

32. (Previously presented) The method of claim 31, wherein said tumor is a breast tumor.

33. (Previously presented) The method of claim 31, wherein said oligonucleotide is at least about 15 nucleotides.

34. (Currently amended) A method of inhibiting the expression of GP88 PC Cell Derived Growth Factor protein in a cell comprising administering a GP88 PC Cell Derived Growth Factor antisense oligonucleotide to the cell wherein said oligonucleotide inhibits the expression of GP88 protein.

35. (Currently amended) A method of inhibiting the proliferation of a tumor cell comprising administering a GP88 PC Cell Derived Growth Factor antisense oligonucleotide to the cell wherein said oligonucleotide inhibits the proliferation of the tumor cell.

36. (Previously presented) The method of claim 35, wherein the proliferation of the tumor cell is inhibited by at least about 80 percent.

37. (Previously presented) The method of claim 35, wherein said tumor cell is a breast carcinoma cell.

38. (New) The method of claim 34, wherein the antisense oligonucleotide is an oligonucleotide targeted to SEQ ID NO:16.